Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, L.; Kerr, Keith M.; Menis, Jessica; Mok, Tony; Nestle, Ursula; Passaro, Antonio; Peters, S.; Planchard, David; Smit, Egbert F.; Solomon, Benjamin J.; Veronesi, Giulia; Reck, Martin

doi:10.1016/j.annonc.2022.12.013

Cited by 227 publications

(152 citation statements)

References 101 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the interpretation of a positive result, its applicability to a particular patient, and the ramifications of cost are essential concerns. The promise of precision medicine comes from specific therapies tailored to the genomic landscape of a patient's tumor, the growing successful avenues of tumor-agnostic therapy, 3,10 the favorable toxicity and better outcome profile of targeted therapy that act on oncogenic drivers, 11 and the indubitable success of immunotherapy. 12 However, this arena is clouded with uncertainty and limitations.…”

Section: Discussionmentioning

confidence: 99%

A Survey on Unmet Need for Uniform Next-Generation Sequencing Reporting in India

Pathak

Kulkarni

et al. 2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction: Next-generation sequencing (NGS) has paved the way for precision oncology in oncology clinics today. With rapidly advancing therapeutics, it is becoming increasingly important to obtain information about the molecular milieu of a patient's tumor. However, reporting and interpreting of NGS is fraught with complexity and variability. To understand the questions surrounding NGS reporting in India, we conducted a survey. Objectives: The aim of this study was to assess the gaps in NGS reporting and interpretation in Indian medical oncology clinics. Materials and Methods: An anonymized 10-question survey-based study among Indian medical oncologists through Google forms was conducted between October 4 and 8, 2022. Results: The sample size was n = 58. Seventy-one percent felt there was heterogeneity in NGS reporting, 72% were unaware of NGS reporting guidelines, and 62% did not feel the need for a molecular scientist assist in NGS interpretation. Almost all (98%) felt there was a need for uniform NGS reporting as well as an Indian NGS repository and data-sharing system (93%). Conclusion: Our survey highlights the need for a uniform national guideline concerning NGS reporting.

show abstract

Section: Discussionmentioning

confidence: 99%

A Survey on Unmet Need for Uniform Next-Generation Sequencing Reporting in India

Pathak

Kulkarni

et al. 2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…Docetaxel with anti-angiogenic agents or single-agent regimens should be considered for further lines of treatment as for non-oncogene-addicted NSCLC. 93 Given the rarity of these alterations, enrolment in clinical trials should be also encouraged.…”

Section: Reviewmentioning

confidence: 99%

“…Given the absence of systematic studies, current guidelines recommend that diseases harbouring non-V600E BRAF mutations should be treated as non-oncogene-addicted NSCLC. 94 Patients with non-V600E BRAF mutations should then receive standard first-line regimens according to PD-L1 levels, and chemotherapy with anti-angiogenic agents thereafter, 93 , 94 and BRAF/MEK inhibition may follow in later lines of treatment. Nevertheless, we deem that physicians facing molecular reports of non-V600 BRAF mutations should interrogate the available literature on melanoma and NSCLC (partially reported here) to look for clinical experience with targeted agents in precise molecular alterations and propose these to pre-treated patients.…”

Section: Reviewmentioning

confidence: 99%

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Guaitoli¹,

Zullo²,

Tiseo³

et al. 2023

DIC

View full text Add to dashboard Cite

BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (classes 2 and 3) relies on their biological characteristics and is of interest for predicting the therapeutic benefit of targeted therapies and immunotherapy. Given the relative rarity of this molecular subset of disease, evidence supporting treatment choices is limited. This review aims to offer a comprehensive update about available therapeutic options for patients with NSCLC harbouring BRAF mutations to guide the physician in the choice of treatment strategies. We collected the most relevant available data, from single-arm phase II studies and retrospective analyses conducted in advanced NSCLC, regarding the efficacy of BRAF and MEK inhibitors in both V600 and non-V600 BRAF mutations. We included case reports and smaller experiences that could provide information on specific alterations. With respect to immunotherapy, we reviewed retrospective evidence on immune-checkpoint inhibitors in this molecular subset, whereas data about chemo-immunotherapy in this molecular subgroup are lacking. Moreover, we included the available, though limited, retrospective evidence of immunotherapy as consolidation after chemo-radiation for unresectable stage III BRAF -mutant NSCLC, and an overview of ongoing clinical trials in the peri-operative setting that could open new perspectives in the future.

show abstract

“…We hypothesized that transcriptomic data analysis can improve patient stratification and may unravel novel treatment approaches for these patients. 1 We developed a bioinformatics pathway-based classification framework using publicly available wholetranscriptome data from more than 2,000 SCC samples focusing on 50 pathways. Previous transcriptome-based classifications used individual gene expression measures, which are prone to multiple sources of variability.…”

Section: E T T E R T O T H E J O U R N a L Transcriptional Profiling ...mentioning

confidence: 99%

“…Lung SCC CPTAC-3 study gene expression and copy number alterations data were downloaded from the Supporting Information. 5 Sara Hijazo-Pechero 1,2,3 Ania Alay 1,2 David Cordero 1,2 Raúl Marín 1,2 Noelia Vilariño 2,4,5 Ramón Palmero 2,4 Jesús Brenes 4 Ernest Nadal 2,4 Xavier Solé…”

Section: O N F L I C T O F I N T E R E S T S Tat E M E N Tmentioning

confidence: 99%

Transcriptional profiling of molecular pathways allows for the definition of robust lung squamous cell carcinoma molecular subtypes with specific vulnerabilities

Hijazo‐Pechero,

Alay,

Cordero

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Cited by 227 publications

References 101 publications

A Survey on Unmet Need for Uniform Next-Generation Sequencing Reporting in India

A Survey on Unmet Need for Uniform Next-Generation Sequencing Reporting in India

Non-small-cell lung cancer: how to manage BRAF-mutated disease

Transcriptional profiling of molecular pathways allows for the definition of robust lung squamous cell carcinoma molecular subtypes with specific vulnerabilities

Contact Info

Product

Resources

About